fig4
![Unraveling the tau puzzle: a review of mechanistic targets and therapeutic interventions to prevent tau pathology in Alzheimer's disease](https://image.oaes.cc/48be6d03-d7e6-492c-8b63-9c49991c8e0a/and3020.fig.4.jpg)
Figure 4. Therapeutic options to mediate intracellular uptake and extracellular release. (1) Competitive binding agents inhibit intracellular uptake via LAG3 and HSPGs[41,45,98-100]. Lysine modification on LRP1 inhibits LRP1-driven intracellular uptake[43]; (2) Tetrodotoxin and Tetanus toxin impair the extracellular release of pathologic tau from axon terminals by blocking the Na+/K+ ATPase and AMPAR pathways, respectively[46,47]. Created with BioRender.com. AMPAR: AMPA receptors; HSPG: heparan sulfate proteoglycan; LAG3: lymphocyte-activation gene 3; LRP1: lipoprotein receptor-related protein 1; TTX: tetrodotoxin.